Corvus Pharmaceuticals, Inc.(NASDAQ : CRVS)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|JNJ||Johnson & Johnson||2.17%||162.84||0.7%||$1339.97m|
|MRK||Merck & Co., Inc.||0.11%||73.42||0.7%||$1168.23m|
|BMY||Bristol-Myers Squibb Co.||1.94%||57.42||1.0%||$788.52m|
|LLY||Eli Lilly & Co.||-1.40%||242.16||1.1%||$715.98m|
|DRNA||Dicerna Pharmaceuticals, Inc.||-0.17%||38.19||0.3%||$148.73m|
|RPRX||Royalty Pharma Plc||1.43%||38.19||0.1%||$114.08m|
|NVO||Novo Nordisk A/S||-0.06%||107.02||0.1%||$85.13m|
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of oncology therapies. The firm focuses on disabling cancerâ€™s ability to subvert immune attack by inhibiting adenosine in the tumor microenvironment and by blocking its production by tumors. Its product pipeline includes B Cell Activator, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.